280TiPGOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer. (25th November 2018)

Record Type:: Journal Article
Title:: 280TiPGOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer. (25th November 2018)
Main Title:: 280TiPGOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer
Authors:: Tewari, K S
Vergote, I
Oaknin, A
Alvarez, E
Gaillard, S
Lheureux, S
Rischin, D
Santin, A D
Feng, M
Mathias, M
Fury, M
Lowy, I
Monk, B J
Abstract:
Is Part Of:: Annals of oncology. Volume 29(2018)Supplement 9
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 9
Issue Display:: Volume 29, Issue 9 (2018)
Year:: 2018
Volume:: 29
Issue:: 9
Issue Sort Value:: 2018-0029-0009-0000
Page Start:
Page End:
Publication Date:: 2018-11-25
Subjects:: Oncology -- Periodicals
616.992
Journal URLs:: https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗
DOI:: 10.1093/annonc/mdy436.027 ↗
Languages:: English
ISSNs:: 0923-7534
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 12251.xml